NASDAQ: LMRILumexa Imaging Holdings Inc Stock
$9.03-0.36 (-3.83%)
Updated Jun 16, 2026
LMRI Price
$9.03
Fair Value Price
N/A
Market Cap
$867.61M
52 Week Low
$6.45
52 Week High
$19.45
P/E
N/A
P/B
1.45x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.94
Operating Cash Flow
N/A
Beta
1.79
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LMRI Overview
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LMRI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LMRI
Ranked#29 of 93
Ranked#29 of 93
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.72 | A | |
| $37.55 | A | |
| $26.43 | A |
Be the first to know about important LMRI news, forecast changes, insider trades & much more!
LMRI News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LMRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LMRI is good value based on its book value relative to its share price (1.45x), compared to the US Medical Devices industry average (3x)
P/B vs Industry Valuation
LMRI's short-term assets ($221.89M) exceed its short-term liabilities ($157.93M)
Short-term Liabilities Financials
LMRI's long-term liabilities ($1.01B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more LMRI due diligence checks available for Premium users.
Valuation
LMRI fair value
Fair Value of LMRI stock based on Discounted Cash Flow (DCF)
Price
$9.03
Fair Value
-$11.18
Undervalued by
180.79%
LMRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
20.94x
Market
13.25x
LMRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.45x
Industry
3x
LMRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LMRI's financial health
Profit margin
Revenue
$252.5M
Net Income
$1.7M
Profit Margin
0.7%
Assets to liabilities
Assets
$1.8B
Liabilities
$1.2B
Debt to equity
1.94
LMRI's short-term assets ($221.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMRI's long-term liabilities ($1.01B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.9M
Investing
-$5.3M
Financing
-$5.3M
LMRI vs Medical Device Stocks
Lumexa Imaging Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.